For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Mucolytic to facilitate expectoration by reducing sputum viscosity.
• Over 5 years: inhalation of nebulised solution (by jet nebuliser), 2,500 units (2.5 mg) once daily (patients over 21 years may benefit from twice daily dosage).
To improve the pulmonary function of cystic fibrosis patients with a forced vital capacity (FVC) of >40% of predicted.
Pulmozyme nebuliser solution, 2.5 mg/2.5 ml ampoules, 30 ampoules
Reduction of sputum viscosity.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic
Osmohale is used for an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness, a clinical feature of some respiratory conditions such as asthma.
Contraindications: Use with caution in renal impairment and to avoid in pregnancy. The Osmohale test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements.
There is limited information on the use of Osmohale in patients 6-18 years of age therefore Osmohale is not recommended in this population.
Dose: See manufacturers’ instructions for more information. The test should be repeated until the patient has a positive response or 635 mg has been administered.